Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.
Positive results were announced from Novo Nordisk’s SUSTAIN 7 Phase III trial comparing once-weekly semaglutide against Lilly’s Trulicity for type 2 diabetes.
House Committee on Oversight and Government Reform Democrats are launching an investigation into why prices for MS treatments have nearly quadrupled since 2004.
Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.
Mylan NV finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment.
One year after emerging from stealth mode, immuno-oncology startup Arcus Biosciences struck an exclusive licensing deal with Shanghai, China-based Wuxi Biologics for its anti-PD-1 antibody GLS-010.
One day after committing to remain on the President’s Manufacturing Council, Johnson & Johnson Chief Executive Officer Alex Gorsky reversed course and resigned from the council, shortly before the council as a whole was disbanded by President Donald Trump.
Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).
The Trump administration will make cost-sharing payments to insurance companies under Obamacare for August 2017, a White House spokesman said, but the announcement did little to quell long-term concerns about the insurance market.